Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells

Cancer Research

Volumn 64, Issue 1, 2004, Pages 252-261

  Boulay, Anne ^a   Zumstein Mecker, Sabine ^a   Stephan, Christine ^a   Beuvink, Iwan ^b   Zilbermann, Frederic ^b   Haller, Roland ^a   Tobler, Sonja ^a   Heusser, Christoph ^a   O'Reilly, Terence ^a   Stolz, Barbara ^a   Marti, Andreas ^a   Thomas, George ^b   Lane, Heidi A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; EVEROLIMUS; FLUOROURACIL; INITIATION FACTOR 4E; RAPAMYCIN DERIVATIVE; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER PATIENT; CHEMICAL ANALYSIS; CHRONOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; EUKARYOTIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PANCREAS TUMOR; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RAT STRAIN; SKIN; TUMOR VOLUME;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MALE; MAP KINASE SIGNALING SYSTEM; PANCREATIC NEOPLASMS; RATS; RATS, INBRED LEW; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIROLIMUS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 9144233506     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-3554-2     Document Type: Article

References (69)

1. Nashan, B. Early clinical experience with a novel rapamycin derivative. Ther. Drug Monit., 24: 53-58, 2002.
2. Huang, S., and Houghton, P. J. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curt. Opin. Investig. Drugs, 3: 295-304, 2002.
3. Mita, M. M., Mita, A., and Rowinski, E. K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer. 4: 126-137, 2003.
4. Hidalgo, M., and Rowinsky, E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19: 6680-6686, 2000.
5. Gingras, A. C., Raught, B., and Sonenberg, N. Regulation of translation initiation by FRAP/mTOR. Genes Dev., 15: 807-826, 2001.
6. Tibbetts, R. S., and Abraham, R. T. PI3K-related kinases: roles in cell-cycle regulation and DNA damage responses. In: J. S. Gutkind (eds.), Signaling Networks and Cell Cycle Control: The Molecular Basis of Cancer and Other Diseases, Vol. 5, pp. 267-301. Totowa, NJ: Humana Press, 2000.
7. Desai, B. N., Myers, B. R., and Schreiber, S. L. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc. Natl. Acad. Sci. USA, 99: 4319-4324, 2002.
8. Hara, K., Yonezawa, K., Weng, Q. P., Kozlowski, M. T., Belham, C., and Avruch, J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem., 273: 14484-14494, 1998.
9. Xu, G., Kwon, G., Marshall, C. A., Lin, T. A., Lawrence, J. C., Jr., and McDaniel, M. L. Branched-chain amino acids are essential in the regulation of PHAS-I and p70 S6 kinase by pancreatic β-cells. A possible role in protein translation and milogenic signaling. J. Biol. Chem., 273: 28178-28184, 1998.
10. Iiboshi, Y., Papst, P. J., Kawasome, H., Hosoi, H., Abraham, R. T., Houghton, P. J., and Terada, N. Amino acid-dependent control of p70(s6k), involvement of tRNA aminoacylation in the regulation. J. Biol. Chem., 274: 1092-1099, 1999.
11. Dennis, P. B., Jaeschke, A., Saitoh, M., Fowler, B., Kozma, S. C., and Thomas, G. Mammalian TOR: a homeostatic ATP sensor. Science (Wash. DC), 294: 1102-1105, 2001.
12. Dufner, A., and Thomas, G., Ribosomal S6 kinase signaling and the control of translation. Exp. Cell Res., 253: 100-109, 1999.
13. 1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem., 273: 14424-14429, 1998.
14. West, M. J., Stoneley, M., and Willis, A. E. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene, 17: 769-780, 1998.
15. Peng, T., Golub, T. R., and Sabatini, D. M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell. Biol., 22: 5575-5584, 2002.
16. Fingar, D. C., Salama, S., Tsou, C., Harlow, E., and Blenis, J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev., 16: 1472-1487, 2002.
17. Scott, P. H., Brunn, G. J., Kohn, A. D., Roth, R. A., and Lawrence, J. C., Jr. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA, 95: 7772-7777, 1998.
18. Nave, B. T., Ouwens, M., Withers, D. J., Alessi, D. R., and Shepherd, P. R. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J., 344: 427-431, 1999.
19. Sekulic, A., Hudson, C. C., Homme, J. L., Yin, P., Otterness, D. M., Kamitz, L. M., and Abraham, R. T. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res., 60: 3504-3513, 2000.
20. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol., 4: 648-657, 2002.
21. Potter, C. J., Pedraza, L. G., and Xu, T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol., 4: 658-665, 2002.
22. Garami, A., Zwartkruis, F. J., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L., and Thomas, G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell, 11: 1457-1466, 2003.
23. Inoki, K., Li, Y., Xu, T., and Guan, K. L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev., 17: 1829-1834, 2003.
24. Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J. Wu, H., and Sawyers, C. L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA, 98: 10314-10319, 2001.
25. Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., Frost, P., Dreisbach, V., Blenis, J., Gaciong, Z., Fisher, P., Sawyers, C., Hedrick-Ellenson, L., and Parsons, R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN+/- mice. Proc. Natl. Acad. Sci. USA, 98: 10320-10325, 2001.
26. Shi, Y., Gera, J., Hu, L., Hsu, J. H., Bookstein, R., Li, W., and Lichtenstein, A. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CC1-779. Cancer Res., 62: 5027-5034, 2002.
27. Lane, H. A., Boulay, A., Hattenberger, M., Maira, S-M., Thomas, G., Merlo, A., and O'Reilly, T. The orally active rapamycin derivative RAD001 has potential as an antitumor agent with a broad antiproliferative activity: PTEN as a molecular determinant of response. Proc. Am. Assoc. Cancer Res., 44: 314, 2003.
28. Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjumenl-Bromage, H., Tempst, P., and Sabatini, D. M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell, 110: 163-175, 2002.
29. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., and Yonezawa, K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell, 110: 177-189, 2002.
30. Kim, D. H., Sarbassov dos, D., Ali, S. M., Latek, R. R., Guntur, K. V., Erdjument-Bromage, H., Tempst, P., and Sabatini, D. M. GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell, 11: 895-904, 2003.
31. Schalm, S. S., and Blenis, J. Identification of a conserved motif required for mTOR signaling. Curr. Biol., 12: 632-639, 2002.
32. Schalm, S. S., Fingar, D. C., Sabatini, D. M., and Blenis, J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol., 13: 797-806, 2003.
33. Nojima, H., Tokunaga, C., Eguchi, S., Oshiro, N., Hidayat, S., Yoshino, K., Hara, K., Tanaka, N., Avruch, J., and Yonezawa, K. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem., 278: 15461-15464, 2003.
34. Gingras, A. C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., and Sonenberg, N. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev., 13: 1422-1437, 1999.
35. Mothe-Satney, I., Brunn, G. J., McMahon, L. P., Capaldo, C. T., Abraham, R. T., and Lawrence, J. C., Jr. Mammalian target of rapamycin-dependent phosphorylation of PHAS-1 in four (S/T)P sites detected by phospho-specific antibodies. J. Biol. Chem., 275: 33836-33843, 2000.
36. Jefferies, H. B., Reinhard, C., Kozma, S. C., and Thomas, G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc. Natl. Acad. Sci. USA, 91: 4441-4445, 1994.
37. Jefferies, H. B., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., and Thomas, G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J., 16: 3693-3704, 1997.
38. Meyuhas, O. Synthesis of the translational apparatus is regulated at the translational level. Eur. J. Biochem., 267: 6321-6330, 2000.
39. Pearson, R. B., Dennis, P. B., Han, J. W., Williamson, N. A., Kozma, S. C., Wettenhall, R. E., and Thomas, G. The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J., 14: 5279-5287, 1995.
40. Peterson, R. T., Beal, P. A., Comb, M. J., and Schreiber, S. L. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J. Biol. Chem., 275: 7416-7423, 2000.
41. Brunn, G. J., Hudson. C. C., Sekulic, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence. J. C., Jr., and Abraham, R. T. Phosphorylation of the translational repressor PHAS-1 by the mammalian target of rapamycin. Science (Wash. DC). 277: 99-101, 1997.
42. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., and Sabatini, D. M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA, 95: 1432-1437, 1998.
43. Beuvink, I., O'Reilly, T., Zumstein-Mecker, S., Zilbermann, F., Sedrani, R., Kozma, S. C., Thomas, G., and Lane, H. A. Antitumor activity of RAD001, an orally active rapamycin derivative. Proc. Am. Assoc. Cancer Res., 42: 366, 2001.
44. O'Reilly, T., Vaxelaire, J., Muller, M., Fiebig, H. H., Hattenberger, M., and Lane, H. A. In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Proc. Am. Assoc. Cancer Res., 43: 71, 2002.
45. Majewski, M., Korecka, M., Kossev, P., Li. S., Goldman, J., Moore, J., Silberstein, L. E., Nowell, P. C., Schuler, W., Shaw, L. M., and Wasik, M. A. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc. Natl. Acad. Sci. USA, 97: 4285-4290, 2000.
46. Majewski, M., Korecka. M., Joergensen, J., Fields, L., Kossev, P., Schuler, W., Shaw, L., and Wasik, M. A. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation. 75: 1710-1717, 2003.
47. Schuler, W., Sedrani, R., Cottens, S., Häberlin, B., Schulz, M., Schuurman, H. J., Zenke, G., Zerwes, H. G., and Schreier, M. H. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation, 64: 36-42, 1997.
48. Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., and Hynes, N. E. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol., 20: 3210-3223, 2000.
49. Olayioye, M. A., Graus-Porta, D., Beerli, R. R., Rohrer, J., Gay, B., and Hynes, N. E. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol. Cell. Biol., 18: 5042-5051, 1998.
50. Lane, H. A., and Thomas, G. Purification and properties of mitogen-activated S6 kinase from rat liver and 3T3 cells. Methods Enzymol., 200: 268-291, 1991.
51. Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., Germain, G. S., Abraham, R. T., and Houghton, P. J. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res., 59: 886-894, 1999.
52. Schuurman, H. J., Cottens, S., Fuchs, S., Joergensen, J., Meerloo, T., Sedrani, R., Tanner, M., Zenke, G., and Schuler, W. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation. 64: 32-35, 1997.
53. Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M., Arbuck, S. G., Travis, R., Sausville, E. A., and Houghton, P. J. Biochemical correlates of mTOR inhibition by the rapamycin ester CC1-779 and tumor growth inhibition. Clin. Cancer Res., 7: 1758-1764, 2001.
54. Jiang, Y. P., Ballou, L. M., and Lin, R. Z. Rapamycin-insensitive regulation of 4E-BP1 in regenerating rat liver. J. Biol. Chem., 276: 10943-10951, 2001.
55. Eng, C. P., Sehgal, S. N., and Vezina, C. Activity of rapamycin (AY-22.989) against transplanted tumors. J. Antibiot., 37: 1231-1237, 1984.
56. Houchens, D. P., Ovejera, A. A., Riblet, S. M., and Slagel, D. E. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur. J. Cancer Clin. Oncol., 19: 799-805, 1983.
57. Geoerger, B., Kerr, K., Tang, C. B., Fung, K. M., Powell, B., Sutton, L. N., Phillips, P. C., and Janss, A. J. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res., 61: 1527-1532, 2001.
58. Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skomicki, J., Frost, P., and Gibbons, J. J. mTOR. a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer, 8: 249-258, 2001.
59. Guba, M., von Breitenbuch, P., Steinbauer Stembauer, M., Koehl, G., Flegel, S., Homung Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., Jauch, K. W., and Geissler, E. K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med., 8: 128-135, 2002.
60. Grewe, M., Gansauge, F., Schmid, R. M., Adler, G., and Seufferlein, T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res., 59: 3581-3587, 1999.
61. Shah, S. A., Potter, M. W., Ricciardi, R., Perugini, R. A., and Callery, M. P. FRAP-p70S6K signaling is required for pancreatic cancer cell proliferation. J. Surg. Res., 97: 123-130, 2001.
62. Kovarik, J. M., Kaplan, B., Tedesco Silva, H., Kahan, B. D., Dantal, J., Vitko, S., Boger, R., and Rordorf, C. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation, 73: 920-925, 2002.
63. Terada, N., Franklin, R. A., Lucas, J. J., Blenis, J., and Gelfand, E. W. Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase. J. Biol. Chem., 268: 12062-12068, 1993.
64. Zenke, G., Strittmatter, U., Fuchs, S., Quesniaux, V. F., Brinkmann, V., Schuler, W., Zurini, M., Enz, A., Billich, A., Sanglier, J. J., and Fehr, T. Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action. J. Immunol., 166: 7165-7171, 2001.
65. Chung, J., Kuo, C. J., Crabtree, G. R., and Blenis, J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell, 69: 1227-1236, 1992.
66. Harding, M. W. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin. Cancer Res., 9: 2882-2886, 2003.
67. Peralba, J. M., deGraffenried, L., Friedrichs, W., Fulcher, L., Grünwald, V., Weiss, G., and Hidalgo, M. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res., 9: 2887-2892, 2003.
68. Stadler, W., Logan, T., Dutcher, J., Hudes, G., Park, Y., Marshall, B., Boni, J., and Dukart, J. A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol., 21: 10a, 2002.
69. O'Donnell, A., Faivre, S., Judson, I., Delbado, C., Brock, C., Lane, H., Shand, N., Hazell, K., Armand, J-P., and Raymond, E. Phase 1 study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours. Proc. Am. Soc. Clin. Oncol., 22: 200, 2003.